September 12, 2022 – Parkinson & Movement Disorder (PMD) Alliance and Neurocrine Biosciences, a neuroscience-focused biopharmaceutical company, announced results from the “Survey Assessment: Impact of OFF Time on People with Parkinson’s Disease and Their Care Partners.” OFF time is a period of time when PD symptoms return between regular doses of carbidopa/levodopa medication. While 78% of people with PD report that their current treatment plan is effective at limiting their PD symptoms, 56% also say that they don’t think their symptoms can improve beyond their current state. A large majority – 86% – of people with PD taking the survey experience OFF time daily.
Nearly all (96%) are willing to explore new treatment options and would ask their doctor about adjunctive therapies. But there’s a general acceptance that the emergence of OFF time is part of the disease with 72% mistakenly believing that adding adjunctive therapy means their PD is progressing.